Table 3 Anticoagulant treatments and genes with variants that potentially affect drug response
From: Application of personalized medicine to chronic disease: a feasibility assessment
Drug name | Brand name | Pharmacogenetic genes | PubMed ID reference | Details |
|---|---|---|---|---|
Warfarin | Coumadin | CYP2C9; VKORC1; CALU; CACNA1C; CYP4F2 | 20200517; | Risk or phenotype-associated alleles. Weekly warfarin dose requirements were lower in those with CYP2C9 loss-of-function alleles as compared with the wild type CYP2C9 genotype |
19794411; | ||||
20072124; | ||||
17341693; | ||||
18250228; | ||||
20203262; | ||||
18535201; | ||||
19297519; | ||||
19300499; | ||||
18535201 | ||||
Dabigatran* | Pradax | |||
Heparin | ||||
Enoxaparin | Lovenox |